HC Wainwright Reiterates Buy Rating for PDS Biotechnology (NASDAQ:PDSB)

PDS Biotechnology (NASDAQ:PDSB)‘s stock had its “buy” rating reaffirmed by investment analysts at HC Wainwright in a research report issued on Thursday, Benzinga reports. They presently have a $21.00 price target on the stock.

Separately, Alliance Global Partners upgraded shares of PDS Biotechnology to a “strong-buy” rating in a research note on Wednesday, August 21st. One equities research analyst has rated the stock with a sell rating, four have assigned a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, PDS Biotechnology presently has a consensus rating of “Moderate Buy” and a consensus target price of $14.25.

PDS Biotechnology Price Performance

Shares of NASDAQ PDSB opened at $3.12 on Thursday. The firm has a market capitalization of $114.26 million, a P/E ratio of -2.29 and a beta of 1.90. The firm’s 50-day moving average price is $3.27 and its 200-day moving average price is $3.27. The company has a current ratio of 3.84, a quick ratio of 3.84 and a debt-to-equity ratio of 0.45. PDS Biotechnology has a 1-year low of $2.53 and a 1-year high of $6.85.

PDS Biotechnology (NASDAQ:PDSB) last posted its quarterly earnings results on Tuesday, August 13th. The company reported ($0.23) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.31) by $0.08. During the same period last year, the company earned ($0.37) EPS. Equities research analysts anticipate that PDS Biotechnology will post -1.24 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the stock. Vanguard Group Inc. boosted its holdings in PDS Biotechnology by 5.5% during the 1st quarter. Vanguard Group Inc. now owns 1,587,806 shares of the company’s stock worth $6,288,000 after acquiring an additional 82,135 shares during the last quarter. Inspirion Wealth Advisors LLC boosted its holdings in PDS Biotechnology by 1.4% during the second quarter. Inspirion Wealth Advisors LLC now owns 359,894 shares of the company’s stock worth $1,054,000 after purchasing an additional 4,917 shares during the last quarter. Blair William & Co. IL boosted its holdings in PDS Biotechnology by 204.4% during the second quarter. Blair William & Co. IL now owns 121,743 shares of the company’s stock worth $357,000 after purchasing an additional 81,743 shares during the last quarter. Cubist Systematic Strategies LLC bought a new stake in PDS Biotechnology in the 2nd quarter worth about $146,000. Finally, Squarepoint Ops LLC purchased a new stake in PDS Biotechnology in the 2nd quarter valued at about $120,000. Hedge funds and other institutional investors own 26.84% of the company’s stock.

PDS Biotechnology Company Profile

PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, developing a pipeline of targeted cancer immunotherapies in the United States. The company's lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, and human papillomavirus associated malignancies.